宜明昂科生物医药技术（上海）股份有限公司（01541）于2026年3月5日发布2月证券变动月报表。公告显示，截至2026年2月28日，公司注册股本总额为人民币431,507,695元，包含已在香港联交所上市的H股420,477,305股和未在香港联交所上市的其他股份11,030,390股，面值均为每股人民币1元。\n\n根据报告期数据，2月并无新增发行、购回或注销股份行为。H股及非上市股份数目分别维持在420,477,305股及11,030,390股，库藏股数目为0股。公司在报告中确认已满足香港联交所上市规则对于公众持股量的要求。\n\n公司同时披露，期内并无涉及股票期权、股权激励或可换股票据相关的股份变动。公告由执行董事、联席公司秘书关梅签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.